ELTP Elite Pharmaceuticals (ELTP) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001053369
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about ELTP
Insiders, 180 days
+$34.6K net bought
1 buyer
Elite Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ELITE PHARMACEUTICALS INC /NV/ insiders bought a net $34.6K of stock across 8 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 19, 2026.
- The trade is 3.0% of the 3,365,555 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Dash Barry H bought about $26.0K of ELTP on Oct 9, 2026, the largest insider purchase at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.9% of the 3,265,555 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Dash Barry H bought about $8.6K of ELTP on Aug 19, 2026, the largest insider purchase at the company since 2025.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 8, 2025.
- The trade is 22.9% of the 3,500,000 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP Operations Plassche Douglas sold about $496.0K of ELTP on Oct 2, 2025, the largest insider sale at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 27.8% of the 1,800,000 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP Operations ELITE PHARMACEUTICALS INC /NV/ sold about $260.0K of ELTP on Aug 22, 2025.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 16,366 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chief Commercial Officer Kirkov Kirko bought about $9.7K of ELTP on Jul 10, 2025, the largest insider purchase at the company on our record.8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$34.6K over 180 days
+$34.6K over 90 days
more than 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+77.1% year over year
more than 82% of Pharma & Biotech
Margin
30.1% net margin
more than 90% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-26) · 2.2 days to cover · settled 2026-09-30
below 85% of Pharma & Biotech
What changed in the last 30 days
Oct 19Director Dash Barry H bought $26.0K (Oct 9)
Watch ELTP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-60.5%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ELTP: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in ELTP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ELTP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $34.6K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
ELTP financials
Revenue growth
+77.1%
XBRL, annual
Net margin
30.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$141.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ELTP
| FY Mar 2026 | $148.9M |
| FY Mar 2025 | $84.0M |
| FY Mar 2024 | $56.6M |
| FY Mar 2023 | $34.2M |
| FY Mar 2022 | $32.3M |
| Jun 2026 | $32.4M |
| Mar 2026 | $40.7M |
| Dec 2025 | $31.6M |
| Sep 2025 | $36.3M |
| Jun 2025 | $40.2M |
| Mar 2025 | $32.0M |
| Dec 2024 | $14.4M |
| Sep 2024 | $18.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+40.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ELTP
| FY Mar 2026 | +30.1% |
| FY Mar 2025 | -5.1% |
| FY Mar 2024 | +35.5% |
| FY Mar 2023 | +10.4% |
| FY Mar 2022 | +27.6% |
| Jun 2026 | +18.3% |
| Mar 2026 | +45.3% |
| Dec 2025 | +58.9% |
| Sep 2025 | +37.7% |
| Jun 2025 | -14.6% |
| Mar 2025 | +53.1% |
| Dec 2024 | -75.8% |
| Sep 2024 | -58.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$17.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ELTP
| FY Mar 2026 | $22.8M |
| FY Mar 2025 | $5.8M |
| FY Mar 2024 | n/a |
| FY Mar 2023 | -$2.4M |
| FY Mar 2022 | $6.0M |
| Jun 2026 | $9.3M |
| Mar 2026 | $8.7M |
| Dec 2025 | -$5.5M |
| Sep 2025 | $5.0M |
| Jun 2025 | $14.6M |
| Mar 2025 | $3.2M |
| Dec 2024 | -$1.1M |
| Sep 2024 | $1.4M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term debt only, 2022-03-31 (51 months older than the period end); equity 2026-06-30
Debt to equity ELTP
| FY Mar 2026 | 0.01x |
| FY Mar 2025 | 0.02x |
| FY Mar 2024 | 0.02x |
| FY Mar 2023 | 0.04x |
| FY Mar 2022 | 0.05x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
15.29x
TTM operating cash flow over long-term debt only, 2022-03-31 (51 months older than the period end)
Cash flow to debt ELTP
| FY Mar 2026 | 19.07x |
| FY Mar 2025 | 5.99x |
| FY Mar 2024 | -2.60x |
| FY Mar 2023 | 2.68x |
| FY Mar 2022 | 5.23x |
| Jun 2026 | 15.29x |
| Mar 2026 | 19.07x |
| Dec 2025 | 14.88x |
| Sep 2025 | 18.26x |
| Jun 2025 | 15.33x |
| Mar 2025 | 5.99x |
| Dec 2024 | 4.53x |
| Sep 2024 | 3.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+74.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ELTP
| FY Mar 2026 | +58.9% |
| FY Mar 2025 | -7.8% |
| FY Mar 2024 | +46.5% |
| FY Mar 2023 | +13.1% |
| FY Mar 2022 | +43.0% |
| Jun 2026 | +74.3% |
| Mar 2026 | +58.9% |
| Dec 2025 | +74.4% |
| Sep 2025 | +25.6% |
| Jun 2025 | -20.4% |
| Mar 2025 | -7.8% |
| Dec 2024 | -43.4% |
| Sep 2024 | -13.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+45.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ELTP
| FY Mar 2026 | +38.2% |
| FY Mar 2025 | -4.8% |
| FY Mar 2024 | +32.3% |
| FY Mar 2023 | +9.4% |
| FY Mar 2022 | +29.0% |
| Jun 2026 | +45.2% |
| Mar 2026 | +38.2% |
| Dec 2025 | +40.0% |
| Sep 2025 | +13.6% |
| Jun 2025 | -10.9% |
| Mar 2025 | -4.8% |
| Dec 2024 | -21.7% |
| Sep 2024 | -8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+43.4%
operating income after a 12.9% effective tax rate, over long-term debt only, 2022-03-31 (51 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ELTP
| FY Mar 2026 | +55.4% |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | +16.3% |
| FY Mar 2022 | n/a |
| Jun 2026 | +43.4% |
| Mar 2026 | +55.4% |
| Dec 2025 | +75.5% |
| Sep 2025 | +51.3% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+33.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ELTP
| FY Mar 2026 | +47.8% |
| FY Mar 2025 | +25.3% |
| FY Mar 2024 | +20.8% |
| FY Mar 2023 | +12.0% |
| FY Mar 2022 | +20.8% |
| Jun 2026 | +33.3% |
| Mar 2026 | +47.8% |
| Dec 2025 | +52.9% |
| Sep 2025 | +46.4% |
| Jun 2025 | +42.9% |
| Mar 2025 | +25.3% |
| Dec 2024 | +18.5% |
| Sep 2024 | +23.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
6.02x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ELTP
| FY Mar 2026 | 18.00x |
| FY Mar 2025 | n/a |
| FY Mar 2024 | 15.00x |
| FY Mar 2023 | n/a |
| FY Mar 2022 | 3.00x |
| Jun 2026 | 9.25x |
| Mar 2026 | 18.00x |
| Dec 2025 | 16.33x |
| Sep 2025 | 64.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$253.7M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term debt only, 2022-03-31 (51 months older than the period end), minus cash 2024-03-31
Enterprise value ELTP
| FY Mar 2026 | $381.9M |
| FY Mar 2025 | $464.2M |
| FY Mar 2024 | $146.8M |
| FY Mar 2023 | $23.8M |
| FY Mar 2022 | $23.0M |
| Jun 2026 | $392.7M |
| Mar 2026 | $381.9M |
| Dec 2025 | $520.6M |
| Sep 2025 | $679.6M |
| Jun 2025 | $774.1M |
| Mar 2025 | $464.2M |
| Dec 2024 | $571.0M |
| Sep 2024 | $410.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.8%
TTM free cash flow over market value at close 2026-10-27
FCF yield ELTP
| FY Mar 2026 | +5.9% |
| FY Mar 2025 | +1.2% |
| FY Mar 2024 | n/a |
| FY Mar 2023 | -7.9% |
| FY Mar 2022 | +19.8% |
| Jun 2026 | +4.4% |
| Mar 2026 | +5.9% |
| Dec 2025 | +3.3% |
| Sep 2025 | +3.2% |
| Jun 2025 | +2.3% |
| Mar 2025 | +1.2% |
| Dec 2024 | +0.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ELTP
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M |
| Net income | $44.9M | -$4.3M | $20.1M | $3.6M |
| EPS (diluted) | 0.03 | 0.00 | 0.02 | 0.00 |
| Operating cash flow | $23.7M | $7.5M | -$3.2M | $3.3M |
| Cash | n/a | n/a | $7.1M | $7.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
ELTP Stock Sonar score 5/7 axes
Find similar shapesCompareELTP ranks highest on profitability (93rd percentile) and financial health (87th), and lowest on risk and compliance (62nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ELTP filings, in plain words
Are Elite Pharmaceuticals insiders buying or selling ELTP?
In the 180 days to 2026-10-28, Elite Pharmaceuticals insiders were net buyers, a net $34.6K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Elite Pharmaceuticals insiders were net buyers of ELTP, a net $34.6K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
